
Data support transferrin vectorised therapy for geographic atrophy
New data have revealed the potential of a DNA plasmid expressing human transferrin for the treatment of dry age-related macular degeneration (AMD) and geographic atrophy (GA). PulseSight Therapeutics shared the data on its lead programme PST-611 at the European Association for Vision and Eye Research (EVER)… Read More
